Obermatt

Lotus Pharmaceutical

TAI:1795 · TW0001795003
PharmaceuticalsMedium

360

19
EV / EBIT61
Price / Owner Earnings39
Owner Earnings Yield76
Dividend Yield81
Price/Sales59
EV / Gross Profit39
Price/Book43
Return on Capital81
Cash Return on Capital63
Return on Equity82
EBIT Margin85
Gross Profitability27
Cash Conversion40
Accruals17
Owner Earnings Margin69
Sales growth100
Profit Growth87
Long-Term EPS Growth36
Owner Earnings Growth40
Reinvestment21
Price momentum46
Debt load1
Refinancing37
Debt Payback10
Liquidity38
Analyst ratings30
Opinion Changes50
Price Target Upside84
Market mood63
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Lotus Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeTWSE
Founded1966
Employees322
ISINTW0001795003
Last UpdateApr 2, 2026
Themes
CardiovascularCentral Nervous SystemObesityOncologyHealth CarePharmaceutical

Description

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products. Business Segments The company operates in two main areas: Asian Business and Export Business. Asian Business This se…

Analysis

Middle-of-the-road

Lotus Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 11.9×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. The financial cushion is thinner than comfortable. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
26
2023202420252026

All-time high

79

Jan 2023

All-time low

26

Jun 2026

Average rank

55

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
59
24
24
69
Price/Earnings
64
74
65
91
Price/Book
43
22
18
47
Dividend Yield
81
67
64
62
Value (overall)
68
38
38
65

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Lotus Pharmaceutical with its peers
Formosa Laboratories
TAI:4746
63
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hanmi Pharmaceutical
KSC:128940
76
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Towa Pharmaceutical
TYO:4553
50
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ilsung IS
KSC:003120
59
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →